Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15–20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is the surgery followed by adjuvant therapy with platinum–etoposide. In stage IIB–IIIC, the recommended treatment is early concurrent chemotherapy with platinum–etoposide plus thoracic radiotherapy followed by prophylactic cranial irradiation in patients without progression. However, in the extensive stage, significant advances have been observed adding immunotherapy to platinum–etoposide chemotherapy to obtain a significant increase in overall survival, constituting the new recommended standard of care. In the second-line treatment, topotecan remains as the standard treatment. Reinduction with platinum–etoposide is the recommended regimen in patients with sensitive relapse (≥ 3 months) and new drugs such as lurbinectedin and immunotherapy are new treatment options. New biomarkers and new clinical trials designed according to the new classification of SCLC subtypes defined by distinct gene expression profiles are necessary.
Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. CrossRef
- De Castro Carpeño J, Cobo Dols M, Domine Gomez M, Ruiz Gracia P, Crama L, Garcia Campelo R. Survival outcomes in stage IV small cell lung cancer (IV-SCLC). Analysis from SEER database. ESMO immuno-oncology congress 2019 (abs 418)
Khan AR, Khan S, Zimmerman V, et al. Quality and strength of evidence of the infectious diseases Society of America Clinical Practice Guidelines. Clin Infect Dis. 2010;51(10):1147–56. CrossRef
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer; 2015.
Amin MB, Greene FL, Byrd DR, et al. American Joint Committee on Cancer (AJCC) cancer staging manual. 8th ed. New York: Springer; 2016. p. 1–1024.
Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung Cancer. 2002;37:271–6. CrossRef
Verma V, Simone CB 2nd, Allen PK, Lin SH. Outcomes of stereotactic body radiotherapy for T1–T2N0 small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation: a multicenter analysis. Clin Lung Cancer. 2017;18:675–81. CrossRef
Yang Y, Zhang D, Zhou X, et al. Prophylactic cranial irradiation in resected small cell lung cancer: a systematic review with meta-analysis. J Cancer. 2018;9:433–9. CrossRef
Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–71. CrossRef
Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18:1116–25. CrossRef
Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30:1692–8. CrossRef
Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20:3054–60. CrossRef
Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22:4837–45. CrossRef
De Ruysscher D, Lueza B, Le Péchoux C, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27:1818–28. CrossRef
Bogart JA, Herndon JE, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004;59:460–8. CrossRef
Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–84. CrossRef
Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99–01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009;10:467–74. CrossRef
Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81:77–84. CrossRef
Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379:2220–9. CrossRef
Reck M, Liu SV, Mansfield AS, et al. IMpower 133: updated overall survival analysis of first-line atezolizumab + carboplatin + etoposide in extensive-stage SCLC. ESMO congress. Barcelona 2019. Ann Oncol 2019; 30 Suppl 5 (abstract 17360).
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39. CrossRef
Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34:3740–8. CrossRef
Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91. CrossRef
Liu ZL, Wang B, Liu JZ, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: a meta-analysis. J Cancer Res Ther 2018;14 (Suppl):S1076–83.
Artal-Cortés A, Gomez-Codina J, Gonzalez-Larriba JL, et al. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer. 2004;6:175–83. CrossRef
Zhou H, Zeng C, Wei Y, Zhou J, Yao W. Duration of chemotherapy for small cell lung cancer: a meta-analysis. PLoS One. 2013;8:e73805. CrossRef
Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72. CrossRef
Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, pase 3 trial. Lancet Oncol. 2017;18:663–71. CrossRef
Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36–42. CrossRef
Palma DA, Warner A, Louie AV, et al. Thoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysis. Clin Lung Cancer. 2016;17:239–44. CrossRef
Baize N, Monnet I, Greillier L, et al. Carboplatin-etoposide versus topotecan as second-line treatment for sensitive relapsed small-cell lung cancer: phase 3 trial. J Thorac Oncol. 2019;14(Suppl):S246. CrossRef
Gong J, Salgia R. Managing patients with relapsed small-cell lung cancer. J Oncol Pract. 2018;14:359–66. CrossRef
Paz-Ares L, Trigo JM, Besse B, et al. Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial. J Clin Oncol 2019; 37 (suppl) (abstr 8605).
Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumabtesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open label, phase 1 study. Lancet Oncol. 2017;18:42–51. CrossRef
Reck M, Vicente D, Ciuleanu T, et al. Efficacy and safety of nivolumab monotherapy versus chemotherapy in recurrent small cell lung cancer: results from CheckMate 331. Ann Oncol 2018;29(Supp 10) (abs LBA5).
Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289–97. CrossRef
Christodoulou M, Blackhall F, Mistry H, et al. Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial. J Thorac Oncol. 2019;14:63–71. CrossRef
Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial: Medical Research Council Lung Cancer Working Party. Lancet. 1996;348:563–6. CrossRef
Feliu J, Heredia-Soto V, Gironés R, et al. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin Transl Oncol. 2019;25:1–11.
Damhuis RAM, Senan S, Belderbos JS. Usage of prophylactic cranial irradiation in elderly patients with small-cell lung cancer. Clin Lung Cancer. 2018;19:263–7. CrossRef
- SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
J. L. Martí
M. E. Olmedo
- Springer International Publishing
Neu im Fachgebiet Onkologie
Mail Icon II